2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 433

Retrospective Analysis Of Certolizumab Pegol Use During Pregnancy: Update Of Impact On Birth Outcomes
Abstract Number: 972

Retrospective Self-Assessment Of Pre-Course Competency: A Useful Tool For Musculoskeletal Curriculum Assessment In a Multi-Center, Interprofessional Cohort
Abstract Number: 444

Reversibility Of Pharmacodynamic Effects After Short- and Long-Term Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
Abstract Number: 1387

Reversing Vascular Dysfunction In Rheumatoid Arthritis: Peroxisome Proliferator-Activated Receptor Gamma Agonist Therapy Improves Augmentation Index But Not Endothelial Function
Abstract Number: 2786

Review Of The Expert Panel Methodology In The Diagnostic and Classification Criteria For Vasculitis Study: A Pilot Study
Abstract Number: 2762

Rheumatoid and Psoriatic Arthritis Are Not Associated With Higher Risk Of Incident Diabetes Mellitus
Abstract Number: 1220

Rheumatoid Arthritis Characteristics and Fracture Risk: A Population-Based Study
Abstract Number: 2308

Rheumatoid Arthritis Flares: Inflammatory Or Avalanche?
Abstract Number: 386

Rheumatoid Arthritis Is Associated With Systemic Inflammation In Coronary Vessels
Abstract Number: 1709

Rheumatoid Arthritis Patient Cardiovascular Disease Prevention Experiences: Qualitative Analysis and Implications
Abstract Number: 181

Rheumatoid Arthritis Quality Measure Results In a Large Managed Care Population
Abstract Number: 1153

Rheumatoid Arthritis Synovial Fibroblasts Lack Tolerization Of Inflammatory Cytokines and Matrix Degrading Enzymes After Repeated LPS Stimulation
Abstract Number: 1653

Rheumatoid Arthritis Synovial IL-21+CD4+ T Cells Specifically Induce Matrix Metalloproteinase Production By Fibroblast-Like Synoviocytes
Abstract Number: 409

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lung Inflammation Evaluated With High Resolution Computed Tomography Scan Is Correlated To Rheumatoid Arthritis Disease Activity
Abstract Number: 2407

Rheumatoid Arthritis-Related Autoantibodies In The Lung Evolve Over Time In Subjects At Elevated Risk For Future Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].